Tumor necrosis factor: How to make a killer molecule tumor-specific?

Current Cancer Drug Targets

Volumn 5, Issue 6, 2005, Pages 381-392

  Lucas, Rudolf ^a,b   Kresse, Matthias ^a   Latta, Markus ^a   Wendel, Albrecht ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b IMC UNIVERSITY OF APPLIED SCIENCES KREMS   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOSTATIN; CASPASE 3; CYCLIC AMP; ENDOSTATIN; FAS ANTIGEN; GELATINASE B; GUANYLATE CYCLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; LECTIN; MELPHALAN; MUSCLE PROTEIN; NITRIC OXIDE; PROTEASOME; PROTEIN BCL XL; RECOMBINANT GAMMA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UBIQUITIN;

ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BRADYCARDIA; BRAIN INJURY; CACHEXIA; CHILL; CLINICAL TRIAL; CYTOSTASIS; CYTOTOXICITY; DRUG CLEARANCE; FATIGUE; FEVER; HEADACHE; HUMAN; HYPOTENSION; IN VIVO STUDY; INNATE IMMUNITY; LETHARGY; LIMB PERFUSION; LIVER PERFUSION; LIVER TOXICITY; LIVER TUMOR; LUNG METASTASIS; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MULTIPLE ORGAN FAILURE; MYELOMA; NONHUMAN; PLASMA HALF LIFE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; SARCOMA; SMOOTH MUSCLE RELAXATION; TREATMENT OUTCOME; TUMOR NECROSIS; TUMOR REGRESSION; TUMOR VASCULARIZATION; WILD TYPE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; LIVER; MELPHALAN; NEOPLASM REGRESSION, SPONTANEOUS; NEOPLASMS; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23844470601     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009054863627     Document Type: Review

References (146)

1. Ebbeil, B. The Papyrus Ebers: the greatest Egyptian medical document. London: Oxford University Press, 1937.
2. Hoption Cann, S. A.; van Netten, J. P.; van Netten, C. Dr. William Coley and tumour regression: a place in history or in the future. Postgrad. Med. J. 2003, 79, 672-680.
3. Coley, W. B. Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and bacillus prodigiosus. Am. J. Med. Sci. 1906, 131, 375-430.
4. Nauts, H. C. The beneficial effects of bacterial infections on host resistance to cancer: end results in 449 cases. 2nd Edition. Monograph No 8. New York: Cancer Res. Inst. 1980.
5. Springer, G. F.; Wang, E. T.; Nichols, J. H.; Shear, J. M. Relations between bacterial lipopolysaccharide structures and those of human cells. Ann. NY Acad. Sci. 1966, 133(2), 566-579.
6. Carswell, E. A.; Old, L. J.; Kassel, R. L.; Green, S.; Fiore, N.; Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 1975, 72, 3666-3670.
7. Marmenout, A.; Fransen, L.; Tavernier, J.; Van der Heyden, J.; Tizard, R.; Kawashima, E.; Shaw, A.; Fiers, W. Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor. Eur. J. Biochem. 1985, 152, 515-522.
8. Shirai, T.; Yamaguchi, H.; Ito, H.; Todd, C. W.; Wallace, R. B. Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature 1985, 131, 803-806.
9. Pennica, D.; Nedwin, G. E.; Hayflick, J. S.; Seeburg, P. H.; Derynck, R.; Palladino, M. A.; Kohr, W. J.; Aggarwal, B. B.; Goeddel, D. V. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984, 312, 724-729.
10. Perez, C.; Albert, I.; DeFay, K.; Zachariades, N.; Gooding, L.; Kriegler, M. A non-secretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 1990, 63(2), 251-258.
11. Black, R. A.; Rauch, C. T.; Kozlosky, C. J.; Peschon, J. J.; Slack, J. L.; Wolfson, M. F.; Castner, B. J.; Stocking, K. L.; Reddy, P.; Srinivasan, S.; Nelson, N.; Boiani, N.; Schooley, K. A.; Gerhart, M.; Davis, R.; Fitzner, J. N.; Johnson, R. S.; Paxton, R. J.; March, C. J.; Cerretti, D. P. A metalloproteinase disintegrin that releases tumour-necrosis factor alpha from cells. Nature 1997, 385, 729-733.
12. Vassalli, P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 1992, 10, 411-452.
13. Sheikh, M. S.; Huang, Y. Death receptors as targets of cancer therapeutics. Curr. Cancer Drug Targets 2004, 4(1), 97-104.
14. Eck, M. J.; Sprang, S. R. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J. Biol. Chem. 1989, 264(29), 17595-17605.
15. Jones, E. Y.; Stuart, D. I.; Walker, N. P. Structure of tumour necrosis factor. Nature 1989, 338(6212), 225-228.
16. Brakebusch, C.; Nophar, Y.; Kemper, O.; Engelmann, H.; Wallach, D. Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor. EMBO J. 1992, 11(3), 943-950.
17. Engelmann, H.; Holtmann, H.; Brakebusch, C.; Avni, Y. S.; Sarov, I.; Nophar, Y.; Hadas, E.; Leitner, O.; Wallach, D. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J. Biol. Chem. 1990, 265(24), 14497-14504.
18. Grell, M.; Douni, E.; Wajant, H.; Lohden, M.; Clauss, M.; Maxeiner, B.; Georgopoulos, S.; Lesslauer, W.; Kollias, G.; Pfizenmaier, K.; Scheurich, P. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995, 83(5), 793-802.
19. Grell, M.; Wajant, H.; Zimmermann, G.; Scheurich, P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc. Natl. Acad. Sci. USA 1998, 95(2), 570-575.
20. Decoster, E.; Vanhaesebroeck, B.; Vandenabeele, P.; Grooten, J.; Fiers, W. Generation and biological characterization of membrane-bound, uncleavable murine tumor necrosis factor. J. Biol. Chem. 1995, 270(31), 18473-18478.
21. Engelmann, H.; Aderka, D.; Rubinstein, M.; Rotman, D.; Wallach, D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. 1989, 264(20), 11974-11980.
22. Engelmann, H.; Novick, D.; Wallach, D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J. Biol. Chem. 1990, 265(3), 1531-1536.
23. Reddy, P.; Slack, J. L.; Davis, R.; Cerretti, D. P.; Kozlosky, C. J.; Blanton, R. A.; Shows, D.; Peschon, J. J.; Black, R. A. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J. Biol. Chem. 2000, 275(19), 14608-14614.
24. Aderka, D.; Engelmann, H.; Maor, Y.; Brakebusch, C.; Wallach, D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 1992, 175(2), 323-329.
25. Wallach, D.; Varfolomeev, E. E.; Malinin, N. L.; Goltsev, Y. V.; Kovalenko, A. V.; Boldin, M. P. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 1999, 17, 331-367.
26. Tartaglia, L. A.; Ayres, T. M.; Wong, G. H.; Goeddel, D. V. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993, 74, 845-853.
27. Lin, R. H.; Hwang, Y. W.; Yang, B. C.; Lin, C. S. TNF receptor-2-triggered apoptosis is associated with the down-regulation of Bcl-xL on activated T cells and can be prevented by CD28 costimulation. J. Immunol. 1997, 158(2), 598-603.
28. Lucas, R.; Garcia, I.; Donati, Y. R.; Hribar, M.; Mandriota, S. J.; Giroud, C.; Buurman, W. A.; Fransen, L.; Suter, P. M.; Nunez, G.; Pepper, M. S.; Grau, G. E. Both TNF receptors are required for direct TNF-mediated cytotoxicity in microvascular endothelial cells. Eur. J. Immunol. 1998, 28(11), 3577-3586.
29. Li, X.; Yang, Y.; Ashwell, J. D. TNF-RII and C-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 2002, 416(6878), 345-347.
30. Robaye, B.; Mosselmans, R.; Fiers, W.; Dumont, J. E.; Galand, P. Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am. J. Pathol. 1991, 138(2), 447-453.
31. Ruegg, C.; Yilmaz, A.; Bieler, G.; Bamat, J.; Chaubert, P.; Lejeune, F. J. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat. Med. 1998, 4(4), 408-414.
32. Rothe, J.; Lesslauer, W.; Lotscher, H.; Lang, Y.; Koebel, P.; Kontgen, F.; Althage, A.; Zinkernagel, R.; Steinmetz, M.; Bluethmann, H. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993, 364, 798-802.
33. Pfeffer, K.; Matsuyama, T.; Kundig, T. M.; Wakeham, A.; Kishihara, K.; Shahinian, A.; Wiegmann, K.; Ohashi, P. S.; Kronke, M.; Mak, T. W. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993, 73, 457-467.
34. Steinshamn, S.; Bemelmans, M. H.; van Tits, L. J.; Bergh, K.; Buurman, W. A.; Waage, A. TNF receptors in murine Candida albicans infection: evidence for an important role of TNF receptor p55 in antifungal defense. J. Immunol. 1996, 157, 2155-2159.
35. Ruby, J.; Bluethmann, H.; Peschon, J. J. Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors. J. Exp. Med. 1997, 186(9), 1591-1596.
36. Lucas, R.; Magez, S.; De Leys, R.; Fransen, L.; Scheerlinck, J. P.; Rampelberg, M.; Sablon, E.; De Baetselier, P. Mapping the lectin-like activity of tumor necrosis factor. Science 1994, 263(5148), 814-817.
37. Magez, S.; Radwanska, M.; Beschin, A.; Sekikawa, K.; De Baetselier, P. Tumor necrosis factor alpha is a key mediator in the regulation of experimental Trypanosoma brucei infections. Infect. Immun. 1999, 67(6), 3128-3132.
38. Cerami, A.; Beutler, B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol. Today 1988, 9(1), 28-31.
39. Bauss, F.; Droge, W.; Mannel, D. N. Tumor necrosis factor mediates endotoxic effects in mice. Infect. Immun. 1987, 55(7), 1622-1625.
40. Grau, G. E.; Fajardo, L. F.; Piguet, P. F.; Allet, B.; Lambert, P. H.; Vassalli, P. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 1987, 237(4819), 1210-1212.
41. Kusters, S.; Tiegs, G.; Alexopoulou, L.; Pasparakis, M.; Douni, E.; Kunstle, G.; Bluethmann, H.; Wendel, A.; Pfizenmaier, K.; Kollias, G.; Grell, M. In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur. J. Immunol. 1997, 27(11), 2870-2875.
42. Lucas, R.; Juillard, P.; Decoster, E.; Redard, M.; Burger, D.; Donati, Y.; Giroud, C.; Monso-Hinard, C.; De Kesel, T.; Buurman, W. A.; Moore, M. W.; Dayer, J. M.; Fiers, W.; Bluethmann, H.; Grau, G. E. Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur. J. Immunol. 1997, 27(7), 1719-1725.
43. Lou, J.; Lucas, R.; Grau, G. E. Pathogenesis of cerebral malaria: recent experimental data and possible applications for humans. Clin. Microbiol. Rev. 2001, 14(4), 810-820.
44. Xu, J.; Lucas, R.; Schuchmann, M.; Kuhnle, S.; Meergans, T.; Barreiros, A. P.; Lohse, A. W.; Otto, G.; Wendel, A. GM-CSF restores innate, but not adaptive, immune responses in glucocorticoid-immunosuppressed human blood in vitro. J. Immunol. 2003, 171(2), 938-947.
45. Xu, J.; Lucas, R.; Wendel, A. The potential of GM-CSF to improve resistance against infections in organ transplantation. Trends Pharmacol. Sci. 2004, 25(5), 254-258.
46. Keane, J.; Gershon, S.; Wise, R. P.; Mirabile-Levens, E.; Kasznica, J.; Schwieterman, W. D.; Siegel, J. N.; Braun, M. M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 2001, 345(15), 1098-1104.
47. Dunn, G. P.; Bruce, A. T.; Ikeda, H.; Old, L. J.; Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002 3(11), 991-998.
48. Coussens, L. M.; Werb, Z. Inflammation and cancer. Nature 2002, 420(6917), 860-867.
49. Harmey, J. H.; Bucana, C. D.; Lu, W.; Byrne, A. M.; McDonnell, S.; Lynch, C.; Bouchier-Hayes, D.; Dong, Z. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int. J. Cancer 2002, 101(5), 415-422.
50. Karin, M.; Cao, Y.; Greten, F. R.; Li, Z. W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002, 2(4), 301-310.
51. Luo, J. L.; Maeda, S.; Hsu, L. C.; Yagita, H.; Karin, M. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell. 2004, 6(3), 297-305.
52. Wang, C. Y.; Cusack, J. C. Jr.; Liu, R.; Baldwin, A. S. Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 1999, 5(4), 412-417.
53. Spriggs, D. R.; Sherman, M. L.; Michie, H.; Arthur, K. A.; Imamura, K.; Wilmore, D.; Frei, E. 3rd.; Kufe, D. W. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J. Natl. Cancer Inst. 1988, 80(13), 1039-1044.
54. Sherman, M. L.; Spriggs, D. R.; Arthur, K. A.; Imamura, K.; Frei, E. 3rd.; Kufe, D. W. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J. Clin. Oncol. 1988, 6(2), 344-350.
55. Giavazzi, R.; Garofalo, A.; Bani, M. R.; Abbate, M.; Ghezzi, P.; Boraschi, D.; Mantovani, A.; Dejana, E. Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res. 1990, 50(15), 4771-4775.
56. Orosz, P.; Echtenacher, B.; Falk, W.; Ruschoff, J.; Weber, D.; Mannel, D. N. Enhancement of experimental metastasis by tumor necrosis factor. J. Exp. Med. 1993, 177(5), 1391-1398.
57. Hafner, M.; Orosz, P.; Kruger, A.; Mannel, D. N. TNF promotes metastasis by impairing natural killer cell activity. Int. J. Cancer 1996, 66(3), 388-392.
58. Chamberlain, J. S. Cachexia in cancer-zeroing in on myosin. N. Engl. J. Med. 2004, 351(20), 2124-2125.
59. Tisdale, M. J. Cancer cachexia. Langenbecks Arch. Surg. 2004, 389(4), 299-305.
60. Acharyya, S.; Ladner, K. J.; Nelsen, L. L.; Damrauer, J.; Reiser P. J.; Swoap, S.; Guttridge, D. C. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J. Clin. Invest. 2004, 114(3), 370-378.
61. Kwak, K. S.; Zhou, X.; Solomon, V.; Baracos, V. E.; Davis, J.; Bannon, A. W.; Boyle, W. J.; Lacey, D. L.; Han, H. Q. Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alpha-II during cancer cachexia. Cancer Res. 2004, 64(22), 8193-8198.
62. Cauwels, A.; Van Molle, W.; Janssen, B.; Everaerdt, B.; Huang, P.; Fiers, W.; Brouckaert, P. Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase. Immunity 2000, 13(2), 223-231.
63. Leist, M.; Gantner, F.; Bohlinger, I.; Germann, P. G.; Tiegs, G.; Wendel, A. Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. J. Immunol. 1994, 153(4), 1778-1788.
64. Leist, M.; Gantner, F.; Jilg, S.; Wendel, A. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J. Immunol. 1995, 154(3), 1307-1316.
65. Lewis, M.; Tartaglia, L. A.; Lee, A.; Bennett, G. L.; Rice, G. C.; Wong, G. H.; Chen, E. Y.; Goeddel, D. V. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc. Natl. Acad. Sci. USA 1991, 88(7), 2830-2834.
66. Van Ostade, X.; Vandenabeele, P.; Everaerdt, B.; Loetscher, H.; Gentz, R.; Brockhaus, M.; Lesslauer, W.; Tavernier, J.; Brouckaert, P.; Fiers, W. Human TNF mutants with selective activity on the p55 receptor. Nature 1993, 361(6409), 266-269.
67. Van Zee, K. J.; Stackpole, S. A.; Montegut, W. J.; Rogy, M. A.; Galvano, S. E.; Hsu, K. C.; Chao, M.; Meschter, C. L.; Loetscher, H.; Stuber, D. et al. A human tumor necrosis factor (TNF) alpha mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon. J. Exp. Med. 1994, 179(4), 1185-1191.
68. Ameloot, P.; Takahashi, N.; Everaerdt, B.; Hostens, J.; Eugster, H. P.; Fiers, W.; Brouckaert, P. Bioavailability of recombinant tumor necrosis factor determines its lethality in mice. Eur. J. Immunol. 2002, 32(10), 2759-2765.
69. Chainy, G. B.; Singh, S.; Raju, U.; Aggarwal, B. B. Differential activation of the nuclear factor-kappa B by TNF mutants specific for the p60 and p80 TNF receptors. J. Immunol. 1996, 157(6), 2410-2417.
70. Shikama, H.; Miyata, K.; Sakae, N.; Mitsuishi, Y.; Nishimura, K.; Kuroda, K.; Kato, M. Novel mutant of tumor necrosis factor alpha (F4614) with reduced hypotensive effect. J. Interferon Cytokine Res. 1995, 15(8), 677-684.
71. Atarashi, Y.; Yasumura, S.; Nambu, S.; Yoshio, Y.; Murakami, J.; Takahara, T.; Higuchi, K.; Watanabe, A.; Miyata, K.; Kato, M. A novel human tumor necrosis factor alfa mutant, F4614, inhibits in vitro and in vivo growth of murine and human hepatoma: implication for immunotherapy of human hepatocellular carcinoma. Hepatology 1998, 28(1), 57-67.
72. Cha, S. S.; Kim, J. S.; Cho, H. S.; Shin, N. K.; Jeong, W.; Shin, H. C.; Kim, Y. J.; Hahn, J. H.; Oh, B. H. High resolution crystal structure of a human tumor necrosis factor-alpha mutant with low systemic toxicity. J. Biol. Chem. 1998, 273(4), 2153-2160.
73. Hession, C.; Decker, J. M.; Sherblom, A. P.; Kumar, S.; Yue, C. C.; Mattaliano, R. J.; Tizard, R.; Kawashima, E.; Schmeissner, U.; Heletky, S.; Muchmore, A. V. Uromodulin (Tamm-Horsfall glycoprotein): a renal ligand for lymphokines. Science 1987, 237(4821), 1479-1484.
74. Sherblom, A. P.; Decker, J. M.; Muchmore, A. V. The lectin-like interaction between recombinant tumor necrosis factor and uromodulin. J. Biol. Chem. 1988, 263(11), 5418-5424.
75. Magez, S.; Geuskens, M.; Beschin, A.; del Favero, H.; Verschueren, H.; Lucas, R.; Pays, E.; de Baetselier P. Specific uptake of tumor necrosis factor-alpha is involved in growth control of Trypanosoma brucei. J. Cell Biol. 1997, 137(3), 715-727.
76. Lucas, R.; Echtenacher, B.; Sablon, E.; Juillard, P.; Magez, S.; Lou, J.; Donati, Y.; Bosman, F.; Van de Voorde, A.; Fransen L.; Mannel, D. N.; Grau, G. E.; de Baetselier, P. Generation of a mouse tumor necrosis factor mutant with antiperitonitis and desensitization activities comparable to those of the wild type but with reduced systemic toxicity. Infect. Immun. 1997, 65(6), 2006-2010.
77. Fukuda, N.; Jayr, C.; Lazrak, A.; Wang, Y.; Lucas, R.; Matalon, S.; Matthay, M. A. Mechanisms of TNF-alpha stimulation of amiloride-sensitive sodium transport across alveolar epithelium. Am. J. Physiol. Lung Cell Mol. Physiol. 2001, 280(6), L1258-L1265.
78. Hribar, M.; Bloc, A.; van der Goot, F. G.; Fransen, L.; De Baetselier, P.; Grau, G. E.; Bluethmann, H.; Matthay, M. A.; Dunant, Y.; Pugin, J.; Lucas, R. The lectin-like domain of tumor necrosis factor-alpha increases membrane conductance in microvascular endothelial cells and peritoneal macrophages. Eur. J. Immunol. 1999, 29(10), 3105-3111.
79. Lucas, R.; Montesano, R.; Pepper, M. S.; Hafner, M.; Sablon, E.; Dunant, Y.; Grau, G. E.; De Baetselier, P.; Mannel, D.; Fransen, L. Lectin-deficient TNF mutants display comparable anti-tumour but reduced pro-metastatic potential as compared to the wild-type molecule. Int. J. Cancer 2001, 91(4), 543-549.
80. Leist, M.; Gantner, F.; Naumann, H.; Bluethmann, H.; Vogt, K.; Brigelius-Flohe, R.; Nicotera, P.; Volk, H. D.; Wendel, A. Tumor necrosis factor-induced apoptosis during the poisoning of mice with hepatotoxins. Gastroenterology 1997, 112(3), 923-934.
81. Leist, M.; Gantner, F.; Kunstle, G.; Wendel, A. Cytokine-mediated hepatic apoptosis. Rev. Physiol. Biochem. Pharmacol. 1998, 133, 109-155.
82. Feldmann, G. Liver apoptosis. J. Hepatol. 1997, 26(Suppl. 2), 1-11.
83. Fausto, N. Liver regeneration. J. Hepatol. 2000, 32(Suppl. 1), 19-31.
84. Rudiger, H. A.; Clavien, P. A. Tumor necrosis factor alpha, but not Fas, mediates hepatocellular apoptosis in the murine ischemic liver. Gastroenterology 2002, 122(1), 202-210.
85. Ashkenazi, A.; Pai, R. C.; Fong, S.; Leung, S.; Lawrence, D. A.; Marsters, S. A.; Blackie, C.; Chang, L.; McMurtrey, A. E.; Hebert, A.; DeForge, L.; Koumenis, I. L.; Lewis, D.; Harris, L.; Bussiere, J.; Koeppen, H.; Shahrokh, Z.; Schwall, R. H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 1999, 104(2), 155-162.
86. Hao, C.; Song, J. H.; Hsi, B.; Lewis, J.; Song, D. K.; Petruk, K. C.; Tyrrell, D. L.; Kneteman, N. M. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res. 2004, 64(23), 8502-8506.
87. Sheridan, J. P.; Marsters, S. A.; Pitti, R. M.; Gurney, A.; Skubatch, M.; Baldwin, D.; Ramakrishnan, L.; Gray, C. L.; Baker, K.; Wood, W. I.; Goddard, A. D.; Godowski, P.; Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277(5327), 818-821.
88. Pan, G.; Ni, J.; Wei, Y. F.; Yu, G.; Gentz, R.; Dixit, V. M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277(5327), 815-818.
89. Jo, M.; Kim, T. H.; Seol, D. W.; Esplen, J. E.; Dorko, K.; Billiar, T. R.; Strom, S. C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 2000, 6(5), 564-567.
90. Lawrence, D.; Shahrokh, Z.; Marsters, S.; Achilles, K.; Shih, D.; Mounho, B.; Hillan, K.; Totpal, K.; DeForge, L.; Schow, P.; Hooley, J.; Sherwood, S.; Pai, R.; Leung, S.; Khan, L.; Gliniak, B.; Bussiere, J.; Smith, C. A.; Strom, S. S.; Kelley, S.; Fox, J. A.; Thomas, D.; Ashkenazi, A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 2001, 7(4), 383-385.
91. Zheng, S. J.; Wang, P.; Tsabary, G.; Chen, Y. H. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J. Clin. Invest. 2004, 113(1), 58-64.
92. Diehl, G. E.; Yue, H. H.; Hsieh, K.; Kuang, A. A.; Ho, M.; Morici, L. A.; Lenz, L. L.; Cado, D.; Riley, L. W.; Winoto, A. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 2004, 21(6), 877-889.
93. Mohammed, F. F.; Smookler, D. S.; Taylor, S. E.; Fingleton, B.; Kassiri, Z.; Sanchez, O. H.; English, J. L.; Matrisian, L. M.; Au, B.; Yeh, W. C.; Khokha, R. Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat. Genet. 2004, 36(9), 969-977.
94. Galle, P. R.; Hofmann, W. J.; Walczak, H.; Schauer, H.; Otto, G.; Stremmel, W, Krammer, P. H.; Runkel, L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 1995, 182(5), 1223-1230.
95. Galle, P. R. Apoptosis in liver disease. J. Hepatol. 1997, 27(2), 405-412.
96. Bradham, C. A.; Plumpe, J.; Manns, M. P.; Brenner, D. A.; Trautwein, C. Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am. J. Physiol. 1998, 275(3 Pt 1), G387-G392.
97. Leist, M.; Single, B.; Castoldi, A. F.; Kuhnle, S.; Nicotera, P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med. 1997, 185(8), 1481-1486.
98. Eguchi, Y.; Shimizu, S.; Tsujimoto, Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res. 1997, 57(10), 1835-1840.
99. Latta, M.; Kunstle, G.; Leist, M.; Wendel, A. Metabolic depletion of ATP by fructose inversely controls CD95- and tumor necrosis factor receptor 1-mediated hepatic apoptosis. J. Exp. Med. 2000, 191(11), 1975-1985.
100. Maenpaa, P. H.; Raivio, K. O.; Kekomaki, M. P. Liver adenine nucleotides: fructose-induced depletion and its effect on protein synthesis. Science 1968, 161(847), 1253-1254.
101. Raivio, K. O.; Kekomaki, M. P.; Maenpaa, P. H. Depletion of liver adenine nucleotides induced by D-fructose. Dose-dependence and specificity of the fructose effect. Biochem. Pharmacol. 1969, 18(10), 2615-2624.
102. Lemasters, J. J.; Qian, T.; Bradham, C. A.; Brenner, D. A.; Cascio, W. E.; Trost, L. C.; Nishimura, Y.; Nieminen, A. L.; Herman, B. Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death. J. Bioenerg. Biomembr. 1999, 31(4), 305-319.
103. Gores, G. J.; Nieminen, A. L.; Fleishman, K. E.; Dawson, T. L.; Herman, B.; Lemasters, J. J. Extracellular acidosis delays onset of cell death in ATP-depleted hepatocytes. Am. J. Physiol. 1988, 255(3 Pt 1), C315-C322.
104. Qian, T.; Herman, B.; Lemasters, J. J. The mitochondrial permeability transition mediates both necrotic and apoptotic death of hepatocytes exposed to Br-A23187. Toxicol. Appl. Pharmacol. 1999, 154(2), 117-125.
105. Lienard, D.; Ewalenko, P.; Delmotte, J. J.; Renard, N.; Lejeune, F. J. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 1992, 10(1), 52-60.
106. Lejeune, F.; Lienard, D.; Eggermont, A.; Schraffordt Koops, H.; Kroon, B.; Gerain, J.; Rosenkaimer, F.; Schmitz P. Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma. Circ. Shock 1994, 43(4), 191-197.
107. Fraker, D. L.; Alexander, H. R.; Andrich, M.; Rosenberg, S. A. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J. Clin. Oncol. 1996, 14(2), 479-489.
108. Alexander, H. R. Jr.; Bartlett, D. L.; Libutti, S. K.; Fraker, D. L.; Moser, T.; Rosenberg, S. A. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J. Clin. Oncol. 1998, 16(4), 1479-1489.
109. Larionov, L. F.; Shkodinskaja, E. N.; Troosheikina, V. I.; Khokhlov, A. S.; Vasina, O. S.; Novikova, M. A. Studies on the anti-tumour activity of p-di-(2-chloroethyl) aminophenylalanine (sarcolysine). Lancet 1955, 269(6882), 169-171.
110. Masta, A.; Gray, P. J.; Phillips, D. R. Nitrogen mustard inhibits transcription and translation in a cell free system. Nucl. Acids Res. 1995, 23(17), 3508-3515.
111. Sarosy, G.; Leyland-Jones, B.; Soochan, P.; Cheson, B. D. The systemic administration of intravenous melphalan. J. Clin. Oncol. 1988, 6(11), 1768-1782.
112. Grunhagen, D. J.; Brunstein, F.; ten Hagen, T. L.; van Geel, A. N.; de Wilt, J. H.; Eggermont, A. M. TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat. Res. 2004, 120, 65-79.
113. Zogakis, T. G.; Bartlett, D. L.; Libutti, S. K.; Liewehr, D. J.; Steinberg, S. M.; Fraker, D. L.; Alexander, H. R. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann. Surg. Oncol. 2001, 8(10), 771-778.
114. ten Hagen, T. L.; Eggermont, A. M. Solid tumor therapy: manipulation of the vasculature with TNF. Technol. Cancer Res. Treat. 2003, 2(3), 195-203.
115. Brouckaert, P.; Takahashi, N.; van Tiel, S. T.; Hostens, J.; Eggermont, A. M.; Seynhaeve, A. L.; Fiers, W.; ten Hagen, T. L. Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. Int. J. Cancer 2004, 109(3), 442-448.
116. Clauss, M.; Gerlach, M.; Gerlach, H.; Brett, J.; Wang, F.; Familletti, P. C.; Pan, Y. C.; Olander, J. V.; Connolly, D. T.; Stern, D. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med. 1990, 172(6), 1535-1545.
117. Berger, A. C.; Alexander, H. R.; Wu, P. C.; Tang, G.; Gnant, M. F.; Mixon, A.; Turner, E. S.; Libutti, S. K. Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte-activating polypeptide II (EMAP-II). Cytokine 2000, 12(7), 992-1000.
118. Kayton, M. L.; Libutti, S. K. Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature. Curr. Opin. Investig. Drugs 2001, 2(1), 136-138.
119. Wu, P. C.; Alexander, H. R.; Huang, J.; Hwu, P.; Gnant, M.; Berger, A. C.; Turner, E.; Wilson, O.; Libutti, S. K. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). Cancer Res. 1999, 59(1), 205-212.
120. Lans, T. E.; Van Horssen, R.; Eggermont, A. M.; Ten Hagen, T. L. Involvement of endothelial monocyte activating polypeptide II in tumor necrosis factor-alpha-based anti-cancer therapy. Anticancer Res. 2004, 24(4), 2243-2248.
121. Ruegg, C.; Mariotti, A. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol. Life Sci. 2003, 60(6), 1135-1157.
122. O'Reilly, M. S.; Holmgren, L.; Shing, Y.; Chen, C.; Rosenthal, R. A.; Moses, M.; Lane, W. S.; Cao, Y.; Sage, E. H.; Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79(2), 315-328.
123. Lucas, R.; Holmgren, L.; Garcia, I.; Jimenez, B.; Mandriota, S. J.; Borlat, F.; Sim, B. K.; Wu, Z.; Grau, G. E.; Shing, Y.; Soff, G. A.; Bouck, N.; Pepper, M. S. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998, 92(12), 4730-4741.
124. Claesson-Welsh, L.; Welsh, M.; Ito, N.; Anand-Apte, B.; Soker, S.; Zetter, B.; O'Reilly, M.; Folkman, J.; Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Natl. Acad. Sci. USA 1998, 95(10), 5579-5583.
125. Hanford, H. A.; Wong, C. A.; Kassan, H.; Cundiff, D. L.; Chandel, N.; Underwood, S.; Mitchell, C. A.; Soff, G. A. Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells. Cancer Res. 2003, 63(14), 4275-4280.
126. O'Reilly, M. S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W. S.; Flynn, E.; Birkhead, J. R.; Olsen, B. R.; Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88(2), 277-285.
127. Dhanabal, M.; Volk, R.; Ramchandran, R.; Simons, M.; Sukhatme, V. P. Cloning, expression, and in vitro activity of human endostatin. Biochem. Biophys. Res. Commun. 1999, 258(2), 345-352.
128. Roh, M. S. Hepatic resection for colorectal liver metastases. Hematol. Oncol. Clin. North Am. 1989, 3(1), 171-181.
129. Ausman, R. K. Development of a technic for isolated perfusion of the liver. NY State J. Med. 1961, 61, 3993-3997.
130. Oldhafer, K. J.; Frerker, M. K.; Lang, H.; Fauler, J.; Flemming, P.; Schmoll, E.; Nadalin, S.; Moreno, L.; Pichlmayr, R. High-dose mitomycin C in isolated hyperthermic liver perfusion for unresectable liver metastases. J. Invest. Surg. 1998, 11(6), 393-400.
131. Ravikumar, T. S.; Pizzorno, G.; Bodden, W.; Marsh, J.; Strair, R.; Pollack, J.; Hendler, R.; Hanna, J.; D'Andrea, E. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J. Clin. Oncol. 1994, 12(12), 2723-2736.
132. Lans, T. E.; Bartlett, D. L.; Libutti, S. K.; Gnant, M. F.; Liewehr, D. J.; Venzon, D. J.; Turner, E. M.; Alexander, H. R. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. Clin. Cancer Res. 2001, 7(4), 784-790.
133. Weinreich, D. M.; Alexander, H. R. Transarterial perfusion of liver metastases. Semin. Oncol. 2002, 29(2), 136-144.
134. Alexander, H. R. Jr.; Bartlett, D. L.; Libutti, S. K.; Fraker, D. L.; Moser, T.; Rosenberg, S. A. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J. Clin. Oncol. 1998, 16(4), 1479-1489.
135. Yamada, Y.; Webber, E. M.; Kirillova, I.; Peschon, J. J.; Fausto, N. Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not type 2 receptor. Hepatology 1998, 28(4), 959-970.
136. Knight, B.; Yeoh, G. C.; Husk, K. L.; Ly, T.; Abraham, L. J.; Yu, C.; Rhim, J. A.; Fausto N. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J. Exp. Med. 2000, 192(12), 1809-1818.
137. Luster, M. I.; Simeonova, P. P.; Gallucci, R. M.; Bruccoleri, A.; Blazka, M. E.; Yucesoy, B.; Matheson, J. M. The role of tumor necrosis factor alpha in chemical-induced hepatotoxicity. Ann. NY Acad. Sci. 2000, 919, 214-220.
138. Simeonova, P. P.; Gallucci, R. M.; Hulderman, T.; Wilson, R.; Kommineni, C.; Rao, M.; Luster, M. I. The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride. Toxicol. Appl. Pharmacol. 2001, 177(2), 112-120.
139. Enomoto, N.; Takei, Y.; Hirose, M.; Ikejima, K.; Miwa, H.; Kitamura, T.; Sato, N. Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production. Gastroenterology 2002, 123(1), 291-300.
140. Sharma, R. P.; Bhandari, N.; Riley, R. T.; Voss, K. A.; Meredith, F. I. Tolerance to fumonisin toxicity in a mouse strain lacking the P75 tumor necrosis factor receptor. Toxicology 2000, 143(2), 183-194.
141. Kresse, M.; Latta, M.; Künstle, G.; Riehle, H.-M.; van Rooijen, N.; Hentze, H.; Tiegs, G.; Biburger, M.; Lucas, R.; Wendel, A. Kupffer cell expressed membrane-bound TNF mediates melphalan hepatotoxicity via activation of both TNF receptors. J. Immunol. 2005, in press.
142. Frankfurt, O. S. Detection of DNA damage in individual cells by flow cytometric analysis using anti-DNA monoclonal antibody. Exp. Cell Res. 1987 170(2), 369-380.
143. Garcia, S. T.; McQuillan, A.; Panasci, L. Correlation between the cytotoxicity of melphalan and DNA crosslinks as detected by the ethidium bromide fluorescence assay in the F1 variant of B16 melanoma cells. Biochem. Pharmacol. 1988, 37(16), 3189-3192.
144. Ulich, T. R.; Guo, K. Z.; Irwin, B.; Remick, D. G.; Davatelis, G. N. Endotoxin-induced cytokine gene expression in vivo. II. Regulation of tumor necrosis factor and interleukin-1 alpha/beta expression and suppression. Am. J. Pathol. 1990, 137(5), 1173-1185.
145. Van Molle, W.; Wielockx, B.; Mahieu, T.; Takada, M.; Taniguchi, T.; Sekikawa, K.; Libert, C. HSP70 protects against TNF-induced lethal inflammatory shock. Immunity 2002, 16(5), 685-695.
146. Adelmann, R. C.; Morris, H. P.; Weinhouse, S. Fructokinase, Triokinase and Aldolase in liver tumors of the rat. Cancer Res. 1967, 27, 2408-2413.